Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.

Date publication

mars 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain

Tous les auteurs :
Boidot R, Blum MGB, Wissler MP, Gottin C, Ruzicka J, Chevrier S, Delhomme TM, Audoux J, Jeanniard A, Just PA, Harter P, Pignata S, González-Martin A, Marth C, Mäenpää J, Colombo N, Vergote I, Fujiwara K, Duforet-Frebourg N, Bertrand D, Philippe N, Ray-Coquard I, Pujade-Lauraine E,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38471290

Résumé

The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies on shallow Whole Genome Sequencing (sWGS) to capture genomic instability and targeted sequencing to determine BRCA status.

Mots clés

BRCA, Genomic instability, Homologous recombination deficiency, Low-pass sequencing, Ovarian cancer, PARP-inhibitor, Whole genome sequencing

Référence

Eur J Cancer. 2024 03 2;202:113978